Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Any Stock Warrants -- Ignore unavailable to you. Want to Upgrade?

To: skywalker44 who wrote (1808)	5/21/2009 12:52:58 PM
From: skywalker44	Read Replies (1) \| Respond to of 1916

Neostem Warrants (NBS-WT) Revisited Shares just hit a 52wk intraday high of $2.17 for this biotech startup. Warrants have not traded today. I see a very wide bid/ask spread of .0201/.07 on NBS-WT at present; bid size of 2400 and ask size of 100. Exercise price is $6.00 and the warrant expiry is 7/16/2012. Share price is very volatile. I'd expect the warrants to move higher from the current level. If one were to pick up warrants at 7-8 cents, let's say, it's hard to gauge whether the bid price would move up to 5-6 cents or so. The lack of liquidity is a downside in my eyes, so I'm not a buyer of the warrants under current conditions. Will keep an eye on this one in the meantime.

To: skywalker44 who wrote (1808)	6/21/2009 1:59:55 PM
From: skywalker44	Read Replies (1) \| Respond to of 1916

Re: Neostem Warrants (NBS-WT) NeoStem was profiled favorably in the June 18, 2009 edition of Business Week (in the Inside Wall Street section) here. The Neostem warrants (NBS-WT) are seldom traded and appear to have very wide bid/ask spreads, therefore I'm not a buyer of these warrants as yet. businessweek.com A Makeover at NeoStem By Gene Marcial BW Magazine NeoStem Big plans by tiny NeoStem (NBS), which collects and stores adult stem cells for future medical use, have helped catapult its stock to 2.27 a share from 50 cents on Mar. 9. NeoStem applied for patent protection in May for a technology that allows use of an adult's stem cells in cosmetic surgery. And it took a 51% stake in a profitable Chinese drug company with $60 million in sales to distribute stem cell therapies in China. In April it raised $11 million in China to improve its balance sheet. It also signed a 10-year pact on June 15 with China's Enhanced Biomed Holdings to build stem cell treatment clinics in China. Rachel Kirsch of Pro-Active Research Group (it did business with NeoStem) rates the stock a speculative buy, seeing it at 5 in a year. Gary Goldstein, president of Mithra Research, says China operations should yield revenues of $50 million a year. His 12-month target: 7. Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.